Immuron Limited (IMRN)

NASDAQ: IMRN · Real-Time Price · USD
1.890
-0.060 (-3.08%)
Nov 6, 2024, 3:34 PM EST - Market open
-3.08%
Market Cap 11.29M
Revenue (ttm) 3.27M
Net Income (ttm) -4.63M
Shares Out 228.00M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,771
Open 1.970
Previous Close 1.950
Day's Range 1.880 - 1.970
52-Week Range 1.481 - 5.960
Beta 1.10
Analysts Strong Buy
Price Target 5.00 (+164.55%)
Earnings Date Nov 19, 2024

About IMRN

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1994
Employees 7
Stock Exchange NASDAQ
Ticker Symbol IMRN
Full Company Profile

Financial Performance

In 2024, Immuron's revenue was 4.90 million, an increase of 171.67% compared to the previous year's 1.80 million. Losses were -6.94 million, 83.2% more than in 2023.

Financial numbers in AUD Financial Statements

Analyst Forecast

According to one analyst, the rating for IMRN stock is "Strong Buy" and the 12-month stock price forecast is $5.0.

Price Target
$5.0
(164.55% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference

MELBOURNE, Australia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be participating in a fireside ...

21 days ago - GlobeNewsWire

Immuron Travelan® continued strong sales growth

MELBOURNE, Australia, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued...

22 days ago - GlobeNewsWire

NMRC Reports Results for Campylobacter Controlled Human Infection Model Study

MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is an Australian based and globally integrated biopharmaceutical company that has developed two commer...

4 weeks ago - GlobeNewsWire

Traveler's Diarrhea Therapeutics Pipeline Market Report 2024 Featuring Immuron, Scandinavian Biopharma, and Sigmoid Pharma

Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Traveler's Diarrhea - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This "Traveler's Diarrhea - Pipeline ...

6 weeks ago - GlobeNewsWire

Immuron Plans Phase 2 Trial for IMM-529 following FDA review

Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) Previous clinical trial data on...

2 months ago - GlobeNewsWire

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024.

2 months ago - GlobeNewsWire

Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®

Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of Travelan. MELBOURNE, Australia, Aug. 16, 2024 (GLOBE NEWSWIRE) -...

2 months ago - GlobeNewsWire

Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference

MELBOURNE, Australia, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that our ...

2 months ago - GlobeNewsWire

Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect

MELBOURNE, Australia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be held...

3 months ago - GlobeNewsWire

Immuron requests pre-IND meeting for IMM-529 with FDA filing

MELBOURNE, Australia, July 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that it ...

4 months ago - GlobeNewsWire

Immuron Board Changes

MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has ...

5 months ago - GlobeNewsWire

Immuron CEO Steven Lydeamore to present at Peak Sky High

MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief E...

5 months ago - GlobeNewsWire

Immuron Limited to Present at the Emerging Growth Conference

MELBOURNE, Australia, May 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite individual a...

6 months ago - GlobeNewsWire

Immuron Director Resignation

MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Stephen Anastasiou ...

6 months ago - GlobeNewsWire

Immuron to host Live Virtual Event

MELBOURNE, Australia, April 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief ...

7 months ago - GlobeNewsWire

Immuron Travelan® sales continued strong growth

Sales Highlights: Global FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcp Mar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter     Australia FYTD Mar 2024 AUD$...

7 months ago - GlobeNewsWire

Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US

Highlights: Immuron proceeding to Phase 3 registration strategy with the FDA Travelan® topline clinical trial results demonstrate protective efficacy with single daily dose 36.4% protective efficacy a...

8 months ago - GlobeNewsWire

Immuron Presentation Australian Biologics Festival 2024

MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Researc...

9 months ago - GlobeNewsWire

Immuron achieves record Travelan® sales

Highlights: Travelan® sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 million Australian Travelan® YTD Jan 2024 sales $2.1 million USA Travelan® YTD Jan 2024 sales $0.6 mil...

9 months ago - GlobeNewsWire

Immuron CEO, Steven Lydeamore Investor Webinar Presentation

MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief E...

9 months ago - GlobeNewsWire

Immuron achieves record half yearly Travelan® sales

Highlights: Record half yearly Travelan® sales of $2,334,969 Total sales of A$2,355,580 in H1, FY24 $1,771,932 increase on H1, FY23 sales 51% higher than pre-pandemic period H1, FY20 sales MELBOURNE, ...

10 months ago - GlobeNewsWire

Immuron Clinical Trials Update

Highlights: US Naval Medical Research Command (NMRC) campylobacter clinical program completes in-patient phase Manufacture of IMM-529 drug substance to support the Pre-IND information package has been...

11 months ago - GlobeNewsWire

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Highlights: First participants enrolled in the US Naval Medical Research Command Clinical Trial Clinical Study initiated to evaluate the efficacy of a new Immuron clinical product to protecting volunt...

1 year ago - GlobeNewsWire

Immuron CEO Steven Lydeamore Investor Webinar Presentation

MELBOURNE, Australia, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholder...

1 year ago - GlobeNewsWire

Immuron CEO Steven Lydeamore presented at AusBioInvest

MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief ...

1 year ago - GlobeNewsWire